PepGen Documents
Documents
100
Ticker
PEPG
ISIN
US7133171055
PepGen SEC Filings
PepGen Documents 2026
This page contains all official documents and SEC filings for PepGen stock (PEPG, ISIN: US7133171055). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of PepGen's regulatory filings.
PepGen Stock analysis
PepGen PepGen Inc., based in Cambridge, Massachusetts, is a biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurologic diseases. The company utilizes its enhanced delivery oligonucleotide (EDO) platform, which employs cell-penetrating peptides to enhance therapeutic delivery. Its lead candidates, PGN-EDO51 for Duchenne muscular dystrophy and PGN-EDODM1 for myotonic dystrophy type 1, are part of a pipeline targeting degenerative conditions. Listed on 6 May 2022, PepGen operates with a team of 56 employees.